Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Circulating nociceptin and CGRP in medication-overuse headache

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Prevention after stroke: A quality assurance study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Does continuous electroencephalography influence therapeutic decisions in neurocritical care?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Transcranial low-frequency pulsating electromagnetic fields (T-PEMF) as post-concussion syndrome treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect and efficacy of lifestyle interventions as secondary prevention

    Research output: Contribution to journalReviewResearchpeer-review

  5. Prevalence and risk of occult cancer in stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Health-related quality of life in tension-type headache: a population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic Susceptibility Loci in Genomewide Association Study of Cluster Headache

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Spontaneous intracranial hypotension presenting with progressive cognitive decline

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Previous studies found low serum levels of nociceptin in migraine patients but high serum levels of calcitonin gene-related peptide (CGRP). CGRP can elicit migraine-like headache. Medication-Overuse Headache (MOH) often has migraine features and can mimic chronic migraine. We therefore hypothesized that as in migraine, serum levels of nociceptin would be lower and CGRP serum levels higher in MOH patients compared with those in healthy volunteers. We hypothesized that the serum levels would normalize after detoxification.

METHODS: Seventeen MOH patients, hereof 70.6% with chronic migraine and MOH, and 30 sex and age matched headache-free controls were included. MOH patients underwent a 2-month outpatient detoxification program and after 6 months, 10 patients and 19 controls were retested. Blood samples were analyzed blinded.

RESULTS: We found no differences in the levels of nociceptin and CGRP between MOH patients and controls (P = 0.65 and P = 0.59). The mean headache frequency reduction was 43% and 70% of patients reverted to episodic headache after 6 months, but the levels of nociceptin and CGRP were unchanged (P = 0.71 and P = 0.82).

CONCLUSION: In contrast to previous findings in migraine patients, we found normal serum levels of nociceptin and CGRP in MOH patients. Thus, we find no evidence that the increased headache frequency of MOH patients could be caused by altered nociceptin and CGRP levels. This underlines the importance of identifying medication overuse in chronic headache and treating the MOH.

Original languageEnglish
JournalActa Neurologica Scandinavica
Volume139
Issue number3
Pages (from-to)269-275
Number of pages7
ISSN0001-6314
DOIs
Publication statusPublished - 1 Mar 2019

    Research areas

  • biomarkers, calcitonin gene-related peptide, chronic migraine, headache pathophysiology, medication-overuse headache, nociceptin

ID: 56704125